Silence Therapeutics (SLN) Operating Expenses (2020 - 2025)
Historic Operating Expenses for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $26.3 million.
- Silence Therapeutics' Operating Expenses rose 19697.05% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 4705.69%. This contributed to the annual value of -$18.9 million for FY2024, which is 6969.67% down from last year.
- Per Silence Therapeutics' latest filing, its Operating Expenses stood at $26.3 million for Q3 2025, which was up 19697.05% from $3.4 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Operating Expenses ranged from a high of $143.1 million in Q4 2023 and a low of -$15.5 billion during Q1 2021
- Its 5-year average for Operating Expenses is -$800.4 million, with a median of -$17.2 million in 2022.
- In the last 5 years, Silence Therapeutics' Operating Expenses soared by 36546.18% in 2021 and then crashed by 8069.51% in 2024.
- Silence Therapeutics' Operating Expenses (Quarter) stood at $119.9 million in 2021, then decreased by 3.54% to $115.6 million in 2022, then increased by 23.76% to $143.1 million in 2023, then crashed by 80.7% to $27.6 million in 2024, then dropped by 4.63% to $26.3 million in 2025.
- Its Operating Expenses was $26.3 million in Q3 2025, compared to $3.4 million in Q2 2025 and $121000.0 in Q1 2025.